CASI Pharmaceuticals Inc (CASI) Given $11.00 Consensus Target Price by Brokerages

Shares of CASI Pharmaceuticals Inc (NASDAQ:CASI) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price objective of $11.00 for the company and are expecting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given CASI Pharmaceuticals an industry rank of 76 out of 255 based on the ratings given to related companies.

CASI has been the subject of several research analyst reports. HC Wainwright set a $7.00 target price on CASI Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 21st. BidaskClub raised CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, December 4th.

NASDAQ CASI traded up $0.01 on Tuesday, reaching $3.31. The company had a trading volume of 4,640 shares, compared to its average volume of 217,701. The firm has a market capitalization of $309.68 million, a P/E ratio of -18.39 and a beta of 1.18. CASI Pharmaceuticals has a 52-week low of $2.73 and a 52-week high of $8.89.

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of CASI Pharmaceuticals by 14.9% during the 4th quarter. Geode Capital Management LLC now owns 584,970 shares of the biotechnology company’s stock worth $2,351,000 after acquiring an additional 75,815 shares during the period. IHT Wealth Management LLC grew its stake in shares of CASI Pharmaceuticals by 121.2% during the 4th quarter. IHT Wealth Management LLC now owns 23,725 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 13,000 shares during the period. Metropolitan Life Insurance Co. NY grew its stake in shares of CASI Pharmaceuticals by 365.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 18,946 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 14,876 shares during the period. Bank of America Corp DE grew its stake in shares of CASI Pharmaceuticals by 132.9% during the 4th quarter. Bank of America Corp DE now owns 28,954 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 16,521 shares during the period. Finally, Wellington Shields & Co. LLC grew its stake in shares of CASI Pharmaceuticals by 20.6% during the 4th quarter. Wellington Shields & Co. LLC now owns 1,080,650 shares of the biotechnology company’s stock worth $4,344,000 after acquiring an additional 184,513 shares during the period. 11.98% of the stock is owned by hedge funds and other institutional investors.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer.

Featured Story: 12b-1 Fees

Get a free copy of the Zacks research report on CASI Pharmaceuticals (CASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.